Aiming at the Right Targets on Drug Price Reform

Journal of Law, Medicine and Ethics 51 (S2):55-57 (2023)
  Copy   BIBTEX

Abstract

A lack of transparency and concerns over patients costs at the pharmacy counter have increased Congressional focus on pharmacy benefits management practices. However, applying regulations without transparency into pharmacy benefits managers practices could do more harm than good.

Categories

Keywords

Reprint years

DOI

10.1017/jme.2023.160

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,323

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Addressing High Drug Prices by Reforming Pharmacy Benefit Managers.Benjamin N. Rome - 2023 - Journal of Law, Medicine and Ethics 51 (S2):46-51.
Why High Drug Pricing Is A Problem for Research Ethics.Spencer Phillips Hey - 2020 - Journal of Bioethical Inquiry 17 (1):29-35.
What Do We Mean When We Call Someone a Drug Addict?Janet Jones - 2020 - Health Care Analysis 28 (4):391-403.
A Drug-taker's Notes by R. H. Ward. (London. Victor Gollancz Ltd. 1957. Pp. 222. Price 16s.).H. H. Price - 1958 - Philosophy 33 (125):168-.
Drug legalization.Douglas N. Husak - 2007 - In Rosamond Rhodes, Leslie Francis & Anita Silvers (eds.), The Blackwell Guide to Medical Ethics. Oxford, UK: Blackwell. pp. 238–253.
Why are Generic Drugs Being Held up in Transit? Intellectual Property Rights, International Trade, and the Right to Health in Brazil and beyond.Mônica Steffen Guise Rosina & Lea Shaver - 2012 - Journal of Law, Medicine and Ethics 40 (2):197-205.
Stimulating the development of drug treatments to improve cognition in schizophrenia.Micahel F. Green - manuscript
生命的哲学 ‐后基因时代药物筛选策略与传统中药学理论.Xiao Ming Wang - 2008 - Proceedings of the Xxii World Congress of Philosophy 44:139-142.
Drug use as consumer behavior.Gordon Robert Foxall & Valdimar Sigurdsson - 2011 - Behavioral and Brain Sciences 34 (6):313-314.
Nonaddictive instrumental drug use: Theoretical strengths and weaknesses.Andrew J. Goudie, Matthew J. Gullo, Abigail K. Rose, Paul Christiansen, Jonathan C. Cole, Matt Field & Harry Sumnall - 2011 - Behavioral and Brain Sciences 34 (6):314-315.
Reauthorization of PDUFA: An Exercise in Post-Market Drug Safety Reform.Peter Chang - 2008 - Journal of Law, Medicine and Ethics 36 (1):196-199.
Drug Proscriptions as Proxy Crimes.Douglas Husak - 2017 - Law and Philosophy 36 (4):345-366.
Drug Advertising, Continuing Medical Education, and Physician Prescribing: A Historical Review and Reform Proposal.Marc A. Rodwin - 2010 - Journal of Law, Medicine and Ethics 38 (4):807-815.
Why do we take drugs? From the drug-reinforcement theory to a novel concept of drug instrumentalization.Rainer Spanagel, Christian P. Müller & Gunter Schumann - 2011 - Behavioral and Brain Sciences 34 (6):322.
Who determines the value of drug-taking behavior? Cultural considerations for a theory of behavioral choice.Riley E. Hinson - 1996 - Behavioral and Brain Sciences 19 (4):580-581.

Analytics

Added to PP
2024-03-05

Downloads
9 (#1,259,126)

6 months
9 (#317,373)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references